A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTI-N-METHYL-DASPARTIC ACID RECEPTOR (NMDAR) OR ANTI-LEUCINE RICH GLIOMA INACTIVATED 1 (LGI1) ENCEPHALITIS.

Registry ID

WN43174

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

HOFFMANN-LA ROCHE LIMITED

Last update

2023-12-20

Conditions

• AUTOIMMUNE ENCEPHALITIS

View on source registry